Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection
Authors:
- Jorge Cg BlancoJBJorge Cg Blanco
- Marina S BoukhvalovaMBMarina S Boukhvalova
- Patrick HemmingPHPatrick Hemming
- Martin G OttoliniMOMartin G Ottolini
- Gregory A PrinceGPGregory A Prince
- 1 December 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 3 (6) , 945-955
Abstract
Respiratory syncytial virus is the leading viral cause of death in children less than 2 years of age, and is an increasing cause of morbidity and mortality in transplant patients and the elderly. Respiratory syncytial virus causes upper and lower respiratory tract infections, which can lead to severe bronchiolitis and pneumonia. High-risk groups for severe respiratory syncytial virus infection include infants with a history of premature birth with or without chronic lung disease, children with congenital heart disease, children with cystic fibrosis or chronic lung diseases, and immunosuppressed patients or patients with immunodeficiency. However, the majority of infants who have severe respiratory syncytial virus disease are born at full term and are otherwise healthy. It is unclear why children, the elderly and the immunosuppressed are at much higher risk for severe disease; however, a respiratory syncytial virus-induced immune pathologic mechanism has long been suspected. Attempts to develop a safe and effective vaccine against respiratory syncytial virus have failed. Antirespiratory syncytial virus immunotherapy, although effective prophylactically, does not provide any beneficial clinical outcome when administered therapeutically, indicating that respiratory syncytial virus-induced pathology is most likely the result of the inflammatory response to infection, rather than a direct viral cytopathic effect. Thus, a combined antiviral and anti-inflammatory therapy may represent the safest and most efficient treatment for acute respiratory syncytial virus infection. In this review, the current knowledge that has set the rationale for the development of such therapy is summarized.Keywords
This publication has 101 references indexed in Scilit:
- Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and GlucocorticosteroidThe Journal of Infectious Diseases, 2000
- Respiratory Syncytial Virus Induces the Expression of 5-Lipoxygenase and Endothelin-1 in Bronchial Epithelial CellsBiochemical and Biophysical Research Communications, 1998
- Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: A randomized, controlled trialThe Journal of Pediatrics, 1997
- Treatment of Parainfluenza Virus Type 3 Bronchiolitis and Pneumonia in a Cotton Rat Model Using Topical Antibody and GlucocorticosteroidThe Journal of Infectious Diseases, 1996
- An Outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant CenterThe Journal of Infectious Diseases, 1992
- Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infectionThe Journal of Pediatrics, 1992
- A new view of prostaglandin E regulation of the immune responseImmunology Today, 1991
- Cellular signalling in programmed cell death (apoptosis)Immunology Today, 1990
- Release of Prostaglandin D2into Human Airways during Acute Antigen ChallengeNew England Journal of Medicine, 1986
- The Development of Respiratory Syncytial Virus-Specific IgE and the Release of Histamine in Nasopharyngeal Secretions after InfectionNew England Journal of Medicine, 1981